UY32670A - Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica - Google Patents

Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica

Info

Publication number
UY32670A
UY32670A UY0001032670A UY32670A UY32670A UY 32670 A UY32670 A UY 32670A UY 0001032670 A UY0001032670 A UY 0001032670A UY 32670 A UY32670 A UY 32670A UY 32670 A UY32670 A UY 32670A
Authority
UY
Uruguay
Prior art keywords
alpha
preparation
treatment
chronic fatigue
fatigue syndrome
Prior art date
Application number
UY0001032670A
Other languages
English (en)
Spanish (es)
Inventor
Quintana Garcia
Alegre Martin Jose
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY32670A publication Critical patent/UY32670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
UY0001032670A 2009-06-30 2010-05-27 Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica UY32670A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (1)

Publication Number Publication Date
UY32670A true UY32670A (es) 2011-01-31

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032670A UY32670A (es) 2009-06-30 2010-05-27 Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica

Country Status (16)

Country Link
US (1) US9205134B2 (https=)
EP (1) EP2289540B1 (https=)
JP (1) JP5231490B2 (https=)
CN (1) CN101934071B (https=)
AR (1) AR077123A1 (https=)
AU (1) AU2010202203B2 (https=)
BR (1) BRPI1002087B1 (https=)
CA (1) CA2706212C (https=)
CL (1) CL2010000575A1 (https=)
ES (2) ES2332645B1 (https=)
MX (1) MX2010006125A (https=)
NZ (1) NZ585890A (https=)
PL (1) PL2289540T3 (https=)
PT (1) PT2289540E (https=)
RU (1) RU2436590C1 (https=)
UY (1) UY32670A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014751A8 (pt) * 2011-12-19 2017-07-04 Lfb Usa Inc composição compreendendo alfa-1-antitripsina, células epiteliais de glândula mamária, mamífero não humano transgênico, e, método para reduzir a atividade de elastase no pulmão
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2001081343A2 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2002006837A1 (en) * 2000-07-14 2002-01-24 Matsushita Electric Industrial Co., Ltd. Particle-labeled protein and immuno-chromatograph using the same
AU2003286258B2 (en) 2002-11-20 2006-12-21 Arriva-Prometic Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US7344882B2 (en) * 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2006026837A1 (en) * 2004-09-07 2006-03-16 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
MX2010003113A (es) * 2007-09-25 2010-04-01 Abbott Lab Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
HUE030205T2 (en) 2007-11-02 2017-05-29 Grifols Therapeutics Inc A method, composition, and product for providing alpha-1-antitrypsin

Also Published As

Publication number Publication date
NZ585890A (en) 2011-11-25
AR077123A1 (es) 2011-08-03
AU2010202203A1 (en) 2011-01-20
CL2010000575A1 (es) 2011-10-28
US9205134B2 (en) 2015-12-08
US20100331261A1 (en) 2010-12-30
CA2706212C (en) 2014-02-04
BRPI1002087A2 (pt) 2012-03-13
EP2289540B1 (en) 2012-08-22
AU2010202203B2 (en) 2012-08-23
EP2289540A1 (en) 2011-03-02
MX2010006125A (es) 2011-01-05
ES2332645B1 (es) 2010-10-18
PL2289540T3 (pl) 2013-03-29
ES2392691T3 (es) 2012-12-12
CN101934071B (zh) 2012-11-28
CN101934071A (zh) 2011-01-05
JP2011012060A (ja) 2011-01-20
BRPI1002087B1 (pt) 2019-07-02
CA2706212A1 (en) 2010-12-30
RU2436590C1 (ru) 2011-12-20
HK1148198A1 (en) 2011-09-02
PT2289540E (pt) 2012-12-04
JP5231490B2 (ja) 2013-07-10
ES2332645A1 (es) 2010-02-09

Similar Documents

Publication Publication Date Title
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
JP2015515475A5 (https=)
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR063958A1 (es) Metodos para administrar medicaciones para la perdida de peso
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
MX2010005107A (es) Componente de silibinina para tratamiento contra hepatitis.
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
JP2016530291A5 (https=)
UY32670A (es) Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
FI3919060T3 (fi) Ecopipam touretten oireyhtymän hoitoon
AR080541A1 (es) Tratamiento para la endometriosis
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210226